GEAP202416461A - Actrii proteins and uses thereof - Google Patents

Actrii proteins and uses thereof

Info

Publication number
GEAP202416461A
GEAP202416461A GEAP202416461A GEAP2024016461A GEAP202416461A GE AP202416461 A GEAP202416461 A GE AP202416461A GE AP202416461 A GEAP202416461 A GE AP202416461A GE AP2024016461 A GEAP2024016461 A GE AP2024016461A GE AP202416461 A GEAP202416461 A GE AP202416461A
Authority
GE
Georgia
Prior art keywords
telangiectasia
risk
effective amount
therapeutically effective
patient treated
Prior art date
Application number
GEAP202416461A
Other languages
English (en)
Georgian (ka)
Inventor
Oliveira Pena Janethe De
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of GEAP202416461A publication Critical patent/GEAP202416461A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
GEAP202416461A 2021-07-19 2022-07-18 Actrii proteins and uses thereof GEAP202416461A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163223265P 2021-07-19 2021-07-19

Publications (1)

Publication Number Publication Date
GEAP202416461A true GEAP202416461A (en) 2024-04-25

Family

ID=84979535

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202416461A GEAP202416461A (en) 2021-07-19 2022-07-18 Actrii proteins and uses thereof

Country Status (18)

Country Link
US (1) US20240327494A1 (https=)
EP (1) EP4373577A4 (https=)
JP (1) JP2024526820A (https=)
KR (1) KR20240049857A (https=)
CN (1) CN117957014A (https=)
AU (1) AU2022316103A1 (https=)
CA (1) CA3225613A1 (https=)
CL (1) CL2024000151A1 (https=)
CO (1) CO2024001551A2 (https=)
CR (1) CR20240061A (https=)
DO (1) DOP2024000016A (https=)
EC (1) ECSP24012819A (https=)
GE (1) GEAP202416461A (https=)
IL (1) IL310141A (https=)
JO (1) JOP20240010A1 (https=)
MX (1) MX2024000829A (https=)
PE (1) PE20240777A1 (https=)
WO (1) WO2023003815A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180055822A1 (en) * 2015-03-13 2018-03-01 Repoceuticals Aps Melatonin for Preventing and Treating Radiation Cystitis
CA3005975A1 (en) * 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
HRP20210694T1 (hr) * 2016-07-15 2021-09-17 Acceleron Pharma, Inc. Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije

Also Published As

Publication number Publication date
CR20240061A (es) 2024-05-02
EP4373577A4 (en) 2025-05-14
CL2024000151A1 (es) 2024-08-09
JP2024526820A (ja) 2024-07-19
CA3225613A1 (en) 2023-01-26
WO2023003815A9 (en) 2023-05-11
KR20240049857A (ko) 2024-04-17
PE20240777A1 (es) 2024-04-17
IL310141A (en) 2024-03-01
WO2023003815A1 (en) 2023-01-26
AU2022316103A1 (en) 2024-02-08
EP4373577A1 (en) 2024-05-29
ECSP24012819A (es) 2024-03-01
US20240327494A1 (en) 2024-10-03
JOP20240010A1 (ar) 2024-01-18
MX2024000829A (es) 2024-04-12
CO2024001551A2 (es) 2024-03-07
CN117957014A (zh) 2024-04-30
DOP2024000016A (es) 2024-06-16

Similar Documents

Publication Publication Date Title
MX2021006681A (es) Anticuerpos anti-claudina y usos de los mismos.
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
CL2023000972A1 (es) Inhibidores de ras
MX2022005359A (es) Inhibidores de ras.
MX2022005357A (es) Inhibidores de ras.
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
GEAP202416461A (en) Actrii proteins and uses thereof
PH12022553106A1 (en) Sars-cov-2-antibodies and methods of selecting and using the same
CY1124238T1 (el) Χρηση αντισωματων κατα της σκληροστινης στη θεραπεια της ατελους οστεογενεσης
CY1125536T1 (el) Συνθεσεις για τη θεραπεια της αμυλοειδωσης
BR112018074152A2 (pt) métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
MX2023011848A (es) Tratamientos contra el prurigo nodular.
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
ZA202106627B (en) Treatment of headache using anti-cgrp antibodies
MX2024014771A (es) Terapia combinada
MX2025000450A (es) Terapia combinada.
WO2021231803A3 (en) Binding molecules for covid-19 treatment
BR112022019454A2 (pt) Composição compreendendo peptídeo vgll1 para tratamento de câncer
MX2021004603A (es) Dosificacion.
EA202092530A1 (ru) Способы облегчения старческой астении и старения
WO2021198346A3 (en) Ezrin peptide 1 for use in a method of treating covid-19
MX2024002584A (es) Tratamientos para la dermatitis atopica.
MX2022002853A (es) Composiciones de neurotoxina para uso en el tratamiento de la gastroparesia.
MX2021014293A (es) Composiciones y métodos para el tratamiento contra hemocromatosis.